Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2019-02-22
Target enrollment:
Participant gender:
Summary
Phase I / II, open, prospective, multicenter single-arm, Clinical Trial in two stages: in the
first stage it will determine the optimal dose of the combination of pazopanib and interferon
alfa-A2 in the treatment of patients with advanced renal carcinoma and a second stage that
will determine the efficacy of this combination measured in terms of response rate.